Finally, although there is little evidence on the anti-inflammatory effects of rhEPO in AD patients, some clinical studies have reported that the inhibition of pro-inflammatory molecules such as TNF-α [177], the increase in HIF [142], and even some related effects with exogenous EPO molecules, could be considered as potential treatments for neurodegenerative diseases [22,76,178]. The gene discussed is EPO; the disease is neurodegenerative disease.